BioSpace News Archive

InMed.AI (InMed Prognostics Inc.), a pioneer in AI-driven predictive analytics using multi-modal data including text, signal, and image (US Patent No.11263749) and the creator of an end-to-end fully automated organ agnostic imaging platform, announced that it has received the US Food and Drug Administration (FDA) 510(k) clearance for NeuroShield™.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that results from the positive Phase 1 clinical trial from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader, were published in Nature Medicine.

Research from Hospital for Special Surgery reveals a significant psychological impact related to inflammatory arthritis patients’ efforts to maintain employment while coping with the challenges of their illness.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received a notice (the “Notice”) from Cboe Canada (“Cboe”) indicating that Awakn is not in compliance with Section 3.01(3) of Cboe’s Listing Manual. Awakn has 90 days to address the non-compliance.

SCG Cell Therapy Pte Ltd (SCG) today announced late-breaking clinical data from its first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy – SCG101 – at the 2023 AASLD Liver Meeting in Boston, United States.

The global narcolepsy therapeutics market size reached USD 3.3 billion in 2022 and is projected to surpass around USD 6.90 billion by 2032, expanding at a CAGR of 7.7% from 2023 to 2032.

People with arthritis who report more negative feelings about how they are aging tend to get less physical activity and perceive themselves as less healthy, according to a new study by researchers at Hospital for Special Surgery and Weill Cornell Medicine.

Brixton Biosciences, a clinical-stage life sciences company developing novel therapies for chronic and acute pain, is delighted to announce that its groundbreaking Coolio™ Therapy has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

Processa Pharmaceuticals, Inc. announced with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023.

Pixium Vision SA announces the conversion of the safeguard proceedings which has been in place since October 9, 2023 into receivership.